Goldman Sachs Group Inc Seres Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
A detailed history of Goldman Sachs Group Inc transactions in Seres Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 14,668 shares of MCRB stock, worth $8,067. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,668
Previous 666,951
97.8%
Holding current value
$8,067
Previous $480,000
97.29%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding MCRB
# of Institutions
82Shares Held
40.5MCall Options Held
304KPut Options Held
471K-
Flagship Pioneering Inc. Cambridge, MA23.1MShares$12.7 Million3.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.06MShares$3.33 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.76MShares$969,1860.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.39MShares$763,7510.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA1.19MShares$656,0110.0% of portfolio
About Seres Therapeutics, Inc.
- Ticker MCRB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,072,000
- Market Cap $68.2M
- Description
- Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...